Many young PhD students and post docs presented their research at the virtual ENCALS meeting, 12-14 May 2021.
The aim of the ENCALS meeting is to allow young researchers for exchange of ideas with peers and with top international investigators.
The poster sessions provided ample opportunity to share new ideas and discuss the exciting developments in the field. Every year the best posters are awarded with an ENCALS Poster Award.
Rapid Fire Poster presentations
A small group of abstracts was selected for a Rapid Fire Poster Presentation during the main programme. In three sessions, a total of 35 presenters was given 3 minutes each to pitch their work. Presentations were judged by the Session Chairs and each day, a winner has been chosen for an ENCALS Poster Award.
The ENCALS Poster Awards for Best Rapid Fire Poster Presentation go to:
- Marta Luisa Gromicho (Lisbon, Portugal)
Dynamic Bayesian networks for stratification of disease progression in ALS
Wednesday, May 12
- Ruxandra Dafinca (Oxford, UK)
Mitochondrial dysfunction links mutations in TDP-43 and C9orf72 iPS-derived motor neurons from ALS patients
Thursday, May 13
- Harold Tan (Utrecht, The Netherlands)
ALS subgroups revealed by clustering neuroimaging patterns of brain degeneration
The selected winners by the public for an ENCALS Poster Award are:
- Sebastian Lewandowski (Stockholm, Sweden)
Perivascular fibroblasts activity precedes the onset of ALS neurodegeneration with high plasma SPP1 associated with short patient survival
- Chen Eitan (Rehovot, Israel)
Non-Coding Genetic Analysis Implicates Interleukin 18 Receptor Accessory Protein 3′UTR in Amyotrophic Lateral Sclerosis
- Mark Doherty (Dublin, Ireland)
journALS: a comprehensive, uniform analysis of three decades of genetics research in amyotrophic lateral sclerosis and frontotemporal dementia
- Eileen Giglia (Dublin, Ireland)
Test-Retest Reliability of EEG Markers of Cognition
- Tijana Ljubikj (Utrecht, The Netherlands)
Dissecting the role of microglia in C9ORF72 ALS using cerebral organoids
- Silvia Pozzi (Quebec, Canada)
Antibodies-based therapy to overcome TDP-43 proteinopathy